France will become the first country in the European Union to reimburse anti-obesity drugs through its public healthcare system, Health Minister Stéphanie Rist announced on Thursday (28 May).
From mid-June, severely obese patients in France will be able to receive partial or full reimbursement for weight-loss injections Wegovy and Mounjaro under the national social security system.
The move marks a major shift in access to obesity treatment in Europe, where the high cost of the drugs has remained a barrier for many patients.
“We are the first country in the European Union to provide reimbursement for patients who need it, under general law, on a permanent basis,” Rist said during an interview with TF1 television.
The treatment will be available to adults with severe obesity who meet strict medical criteria.
Patients with a body mass index (BMI) of at least 35 and at least one obesity-related illness will qualify. Those with a BMI of 40 or above will also be eligible, even without additional health conditions.
The drugs will officially be reimbursed at a rate of 65%. However, Rist said most eligible patients are likely to receive full coverage because many already qualify for 100% reimbursement due to related medical conditions.
“The target population is around one million people. However, this does not mean that everyone will receive the treatment, as it always depends on the individual case and the doctor’s prescription,” she said.
Wegovy, produced by Danish pharmaceutical company Novo Nordisk, and Eli Lilly’s Mounjaro have become some of the world’s most sought-after obesity treatments in recent years.
The drugs help patients lose weight by regulating appetite and blood sugar levels. Demand has surged globally as governments and healthcare systems seek ways to tackle rising obesity rates.
In France, the treatments have been available by prescription since 2024, but patients have until now had to cover the cost themselves. Monthly treatment costs average around €300.
Rist estimated the reimbursement programme would eventually cost the French state around €100 million per year as prescriptions increase.
Last year, France also widened access by allowing all doctors, not just specialists such as endocrinologists, to prescribe the treatments.
According to a French study published in 2024, around 18% of France’s population - roughly 10 million people - are obese.
As of January this year, more than 70,000 patients in France were already being treated with Mounjaro, according to estimates.
Health officials said the reimbursement programme is intended to help patients suffering from chronic obesity-related conditions rather than support cosmetic weight loss.
“It addresses a growing public health challenge and the urgency of appropriate therapeutic care,” said Étienne Tichit, General Manager of Novo Nordisk France.
Mike Doustdar, president and chief executive of Novo Nordisk, said the decision showed “the foresight and maturity of the French system.”
The decision comes as competition in the obesity drug market continues to intensify.
Novo Nordisk and Eli Lilly have both launched oral versions of their weight-loss treatments in the U.S. Last week, the European Medicines Agency recommended approval of Novo Nordisk’s Wegovy pill, which could become the first oral anti-obesity drug available in Europe.
In the UK, weight-loss drugs including Wegovy and Mounjaro are available on the NHS, but access remains limited under strict eligibility criteria. Patients typically need to meet BMI thresholds and have obesity-related health conditions.
Gen Z protests swept 34 German cities on Saturday (31 October) over education, living costs and military service proposals. Violence erupted in Fra...
Iran designated Britain's Royal Navy and Royal Air Force as terrorist organisations on Sunday, (1 November), and classified the country's f...
Since 2021, only 9 per cent of $8 billion in humanitarian aid for Afghanistan can be traced beyond initial recipients in public re...
The U.S. has approved the sale of 500 Patriot PAC-3 missiles to Ukraine in a deal worth an estimated $2.1 billion, but Kyiv could face years of delays before receiving the weapons it urgently needs to defend against intensifying Russian attacks.
Iranian Supreme Leader Ayatollah Khamenei has ordered Iran's armed forces to respond to any threat immediately and without geographical limits in statements posted to social media platforms on Saturday (31 October).
Demonstrators carrying Iranian flags and placards supporting the hijab gathered outside the Azerbaijani Embassy in London.
A Chinese-made AI chip has matched Nvidia’s H200 in tests conducted by its developer, marking a potential breakthrough in China’s efforts to reduce its dependence on foreign technology.
A hacking group linked to North Korea is widely believed to be behind the theft of $6.3 billion from cryptocurrency giant Binance, a cyberattack that experts describe as the largest cryptocurrency heist on record.
Gen Z protests swept 34 German cities on Saturday (31 October) over education, living costs and military service proposals. Violence erupted in Frankfurt, where shops were looted and police reported Molotov cocktail attacks.
Iran designated Britain's Royal Navy and Royal Air Force as terrorist organisations on Sunday, (1 November), and classified the country's foreign intelligence agency, MI6, as a hostile group, according to a statement from the Iranian Foreign Ministry.
Thousands protested in Albania's capital, Tirana, on Saturday (31 October), demanding Prime Minister Edi Rama's resignation over perceived corruption allegations and dissatisfaction with the government over a lack of jobs and poor education standards.
Russia has agreed to work with Ghana on developing a 2,000-megawatt nuclear power plant following talks at the Russia-Africa Summit in Moscow, Ghanaian Foreign Minister Samuel Okudzeto Ablakwa said on Saturday.
Foreign ministers from the U.S., Japan, Australia and India raised concerns over export restrictions and economic coercion at a Quad meeting in Atlanta, U.S., on Saturday, 31 October 2026, according to their joint statement.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment